Chang Feng | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Chang Feng | Cancer Cell Biology | Best Researcher Award

Dr. Chang Feng , Shanghai University , China

Chang Feng is a distinguished researcher in the fields of tumor molecular diagnosis, biosensing, and intelligent DNA. Born in Shanghai, China, on January 1, 1988, Chang Feng pursued a rigorous academic journey, completing his Ph.D. at Nanjing University (2015-2019) after earning his M.D. from Shanghai University (2012-2015). He is currently a lecturer at Shanghai University since 2019. Feng has contributed significantly to scientific advancements in cancer diagnostics, molecular biosensors, and cutting-edge DNA research. His works often involve the development of innovative detection techniques and the creation of novel DNA-based diagnostic systems. Feng has a collaborative approach, working with multiple researchers to achieve groundbreaking results. His publications in prestigious journals highlight his expertise in developing biosensors, RNA origami, and catalytic DNAzymes for biomedical applications.

Publication Profile: 

Scopus

Strengths for the Award:

Chang Feng’s research is exceptional and well-suited for the Best Researcher Award. His expertise spans across tumor molecular diagnosis, biosensor development, and intelligent DNA systems. His contributions to cancer diagnostics, bioimaging, and biosensing technologies are groundbreaking. Feng has published several high-impact articles in leading journals, demonstrating significant advancements in DNAzymes, electrochemical biosensing, and RNA origami. His work in designing innovative DNA-based diagnostic platforms and cancer therapies reflects his ability to integrate chemistry, biology, and engineering, providing novel solutions for clinical applications. Feng’s interdisciplinary approach and leadership in the field have earned him numerous collaborations with researchers and institutions globally, further enhancing his credibility as a top-tier researcher.

Areas for Improvements:

While Feng has made remarkable contributions to scientific research, one area for improvement is expanding his focus to more clinical applications of his findings. Commercializing his biosensing technologies for real-world healthcare implementation would increase the practical impact of his work. Additionally, improving outreach through public science communication could help raise awareness of his advancements and engage a broader audience.

Education:

Chang Feng received his M.D. from Shanghai University in 2015, where he developed a strong foundation in molecular biology, diagnostics, and bioengineering. His doctoral journey continued at Nanjing University (2015-2019), where he obtained his Ph.D. focusing on tumor molecular diagnosis and biosensing technologies. During his time at Nanjing University, Feng’s research concentrated on the development of DNA-based biosensors and new methodologies for cancer detection. His education at these esteemed institutions provided him with the technical expertise necessary to pioneer groundbreaking research in the field of molecular diagnostics. Feng’s academic training involved rigorous coursework in molecular biology, chemical engineering, and bioinformatics, contributing significantly to his current work in bioimaging, biosensing, and the development of intelligent DNA systems.

Experience:

Chang Feng has a strong academic and research career, currently serving as a lecturer at Shanghai University since 2019. Prior to his current role, he earned his Ph.D. at Nanjing University (2015-2019) and M.D. from Shanghai University (2012-2015). Throughout his career, Feng has collaborated with leading researchers, contributing to the development of innovative biosensing technologies and cancer diagnostics. His work includes advancing DNA-based biosensors, DNAzyme probes, and other cutting-edge diagnostic tools. As a lecturer, Feng mentors graduate students and participates in academic teaching and research projects. He has been involved in several collaborative publications that have furthered the field of molecular biosensors, focusing on intelligent DNA-based systems and tumor detection methodologies. Feng’s research experience combines theoretical knowledge with practical applications, making him a recognized figure in the field of biosensor research and molecular diagnostics.

Research Focus:

Chang Feng’s primary research focus lies in tumor molecular diagnosis, biosensor development, and intelligent DNA systems. He is particularly interested in advancing technologies for cancer detection through the application of molecular biosensors, bioimaging, and intelligent DNA devices. His research explores the use of DNAzymes, catalytic DNA molecules, and RNA origami for targeted molecular detection, with a focus on enhancing the sensitivity and specificity of cancer diagnostics. Feng’s work also investigates the use of biosensors for the detection of small molecules, leveraging innovative electrochemical and fluorescence-based platforms. His interdisciplinary approach combines elements of chemistry, biology, and engineering to create advanced diagnostic systems with potential clinical applications. Feng is dedicated to improving the efficiency of diagnostic tools and is committed to developing more accurate and faster methods for early cancer detection and molecular analysis.

Publications Top Notes:

  1. Single-cell analysis of highly metastatic circulating tumor cells by combining a self-folding induced release reaction with a cell capture microchip 🧬🔬 (Anal. Chem., 2021)
  2. Hierarchical biomarkers detection via a universal polydopamine probe catalyzed by a hexagonal star-nanostructured DNAzyme 🔬🧪 (Sensor. Actuat. B-Chem., 2022)
  3. Construction of a ternary complex based DNA logic nanomachine for a highly accurate imaging analysis of cancer cells 🧬💡 (ACS Sens., 2020)
  4. Lantern-shaped flexible RNA origami for Smad4 mRNA delivery and growth suppression of colorectal cancer 🧬🦠 (Nat. Commun., 2023)
  5. Liquid-colloid-solid modular assembly for three-dimensional electrochemical biosensing of small molecules 💧⚡ (Biosens. Bioelectron., 2024)
  6. Dual-targets binding protection mediated rolling circle transcription with tandem fluorescent RNA aptamers for label-free detection of liver cancer biomarkers 🧬🦠 (Sensor. Actuat. B-Chem., 2024)
  7. Cell-Free Biosensing Genetic Circuit Coupled with Ribozyme Cleavage Reaction for Rapid and Sensitive Detection of Small Molecules 🧬⚡ (ACS Synth. Biol., 2023)
  8. A portable and partitioned DNA hydrogel chip for multitarget detection 💧🧬 (Lab Chip., 2023)

Conclusion:

Chang Feng’s research in tumor molecular diagnostics, biosensors, and intelligent DNA is truly cutting-edge. His scientific rigor, collaboration with top researchers, and groundbreaking discoveries in cancer detection and biosensing technologies make him a deserving candidate for the Best Researcher Award. By continuing to bridge the gap between laboratory research and clinical applications, Feng will likely have an even greater impact in advancing medical diagnostics and therapeutic strategies.

Guangxun Meng | Cancer Immunology | Cancer Cell Biology Award

Posted on by sciencefather

Prof. Guangxun Meng | Cancer Immunology | Cancer Cell Biology Award

Prof. Guangxun Meng , Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences , China

Guangxun Meng is the Lab Chief of the Innate Immunity Lab at the Shanghai Institute of Immunity and Infection, CAS, China. He specializes in mucosal immunology and inflammasome research, with a focus on barrier organs such as the gut, lung, and skin. His work is instrumental in understanding viral infections, inflammation, and cancer, particularly within the respiratory system and gut. With numerous high-impact publications, Guangxun’s contributions to immunology have significantly advanced understanding in innate immunity and the inflammasome’s role in disease. His ongoing research projects include exploring novel therapeutics for cancer suppression and viral infections.

Publication Profile:

Google Scholar

Strengths for the Award:

Dr. Guangxun Meng has made substantial contributions to the fields of mucosal immunology, inflammation, and cancer, particularly through his work on the inflammasome and innate immunity. His research has been pivotal in understanding the roles of NLRP3 and IL-18 in immune responses and cancer suppression. Dr. Meng’s work has led to significant advancements, such as the discovery of short IL-18 and its mobilization of NK cells to suppress tumor growth. His innovative work, which links microbiota, inflammasomes, and viral immunity, has been published in prestigious journals like Nature Immunology and Nature Communications. The breadth of his patents, including those targeting viral infections, further highlights his innovative contributions to the field.

Areas for Improvement:

While Dr. Meng’s research has made significant strides in understanding immune responses in cancer, further investigation into the therapeutic applications of his findings would be beneficial. Expanding collaborations with clinical researchers could bridge the gap between basic science and clinical oncology, potentially leading to novel treatment options.

Education:

Guangxun Meng earned his advanced degrees at leading institutions, where he developed a strong foundation in immunology and molecular biology. He completed his postdoctoral training in immunology and infectious diseases, deepening his understanding of immune responses to viral infections and their regulation in mucosal tissues. Throughout his career, he has focused on integrating experimental immunology with clinical insights to discover new therapeutic strategies, making him a prominent figure in his field.

Experience:

Guangxun Meng’s extensive research experience spans key roles in both academia and collaborative projects with the biotech industry. As Lab Chief at the Shanghai Institute of Immunity and Infection, he leads a team focused on understanding the mechanisms of mucosal immunity and inflammation. His research spans multiple areas, including cancer immunotherapy, viral infections, and the inflammasome’s role in diseases like sepsis. Over the years, Guangxun has worked with leading immunologists worldwide, contributing significantly to research on innate immunity, microbial interactions, and cancer biology.

Awards and Honors:

Guangxun Meng has received numerous accolades throughout his career for his groundbreaking contributions to immunology and cancer research. He is a respected member of several prestigious scientific societies, including the Society for Mucosal Immunology and the American Association of Immunologists. His work has led to significant advances in the fields of inflammation and viral infections, and his lab continues to receive recognition for the potential clinical applications of its research. His contributions to immunology have made him a leading expert in the study of inflammasomes and mucosal immunity.

Research Focus:

Guangxun Meng’s primary research focuses on mucosal immunology, inflammasome activation, and innate immunity. His work investigates the immune responses in barrier organs like the gut, skin, and lungs, particularly in relation to viral infections, inflammation, and cancer. He is exploring the therapeutic potential of novel molecules like short IL-18 and the role of microbiota-derived metabolites, such as short-chain fatty acids, in immune modulation. His lab’s research also includes the development of new strategies to target inflammasome activation and improve responses to infections and cancer.

Publications Top Notes:

  1. Short IL-18 generated by caspase-3 cleavage mobilizes NK cells to suppress tumor growth – Nature Immunology 📄
  2. Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission – eLife 🦠
  3. Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2 – Antiviral Res. 💊
  4. Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2 – PLoS Pathogens 🧪
  5. cFLIPS regulates alternative NLRP3 inflammasome activation in human monocytes – Cell Mol Immunol 💡
  6. TRAF6-TAK1-IKKβ pathway mediates TLR2 agonists activating “one-step” NLRP3 inflammasome – Cytokine 🔬
  7. TAK1 Deficiency in Macrophages Increases Host Susceptibility to Leishmania Infection – Infectious Microbes & Diseases 🦠
  8. Function of NLRP3 in Anti-influenza Viral Infection – Viruses 🦠
  9. Microbiota-derived acetate enhances host antiviral response via NLRP3 – Nature Communications 🌿
  10. SARS-CoV-2 spike engagement of ACE2 primes S2’site cleavage and fusion initiation – Proc Natl Acad Sci USA 🦠

Conclusion:

Dr. Guangxun Meng is highly deserving of the Research for Cancer Cell Biology Award. His pioneering work in immunology, inflammasomes, and cancer biology represents a critical contribution to the understanding of immune responses in cancer. His research promises to have significant implications for both cancer therapy and infectious disease control.